Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APECS: Verubecestat in Prodromal AD
NCT01953601Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2013
- Primary completion
- Apr 2018
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of verubecestat in Alzheimer's disease (AD), sponsored by Merck & Co.. Started Nov 2013; status: terminated.
02
Drugs
verubecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01953601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01953601.